Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Inhibition of leukocyte adhesion to the vascular endothelium represents a novel and important approach for decreasing sickle cell disease (SCD) vaso-occlusion. Using a humanized SCD–mouse-model of tumor necrosis factor-α–induced acute vaso-occlusion, we herein present data demonstrating that short-term administration of either hydroxyurea or the phosphodiesterase 9 (PDE9) inhibitor, BAY73-6691, significantly altered leukocyte recruitment to the microvasculature. Notably, the administration of both agents led to marked improvements in leukocyte rolling and adhesion and decreased heterotypic red blood cell-leukocyte interactions, coupled with prolonged animal survival. Mechanistically, these rheologic benefits were associated with decreased endothelial adhesion molecule expression, as well as diminished leukocyte Mac-1-integrin activation and cyclic guanosine monophosphate (cGMP)–signaling, leading to reduced leukocyte recruitment. Our findings indicate that hydroxyurea has immediate beneficial effects on the microvasculature in acute sickle-cell crises that are independent of the drug's fetal hemoglobin-elevating properties and probably involve the formation of intravascular nitric oxide. In addition, inhibition of PDE9, an enzyme highly expressed in hematopoietic cells, amplified the cGMP-elevating effects of hydroxyurea and may represent a promising and more tissue-specific adjuvant therapy for this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 1×
“), a scavenger of NO that does not affect NOS; or the guanylate cyclase inhibitor, 1H-[1,2,4] oxadiazolo [4,3-a]quinoxalin-”
BackgroundEffect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T. (2002) · Nature Medicine · doi:10.1038/nm1202-799 · Cited by 1,330
Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876
Transgenic Knockout Mice with Exclusively Human Sickle Hemoglobin and Sickle Cell Disease
Pászty, C., Brion, C. M., Manci, E., Witkowska, H. E., Stevens, M. E., Mohandas, N., & Rubin, E. M. (1997) · Science · doi:10.1126/science.278.5339.876 · Cited by 467
GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice
Chang, J., Patton, J. T., Sarkar, A., Ernst, B., Magnani, J. L., & Frenette, P. S. (2010) · Blood · doi:10.1182/blood-2009-12-260513 · Cited by 238
Self-citationSodium nitrite promotes regional blood flow in patients with sickle cell disease: a phase I/II study
Mack, A. K., McGowan II, V. R., Tremonti, C. K., Ackah, D., Barnett, C., Machado, R. F., Gladwin, M. T., & Kato, G. J. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07259.x · Cited by 64
Research works printed but not linked: 43
- Stuart, 2004, Sickle-cell disease., Lancet, 364, 1343, 10.1016/S0140-6736(04)17192-4 · DOI · Paper page
- Hebbel, 1980, Erythrocyte adherence to endothelium in sickle-cell anemia: a possible determinant of disease severity., N Engl J Med, 302, 992, 10.1056/NEJM198005013021803 · DOI · Paper page
- Frenette, 2007, Sickle cell disease: old discoveries, new concepts, and future promise., J Clin Invest, 117, 850, 10.1172/JCI30920 · DOI · Paper page
- Turhan, 2002, Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm., Proc Nat Acad Sci U S A, 99, 3047, 10.1073/pnas.052522799 · DOI · Paper page
- Belcher, 2003, Transgenic sickle mice have vascular inflammation., Blood, 101, 3953, 10.1182/blood-2002-10-3313 · DOI · Paper page
- Aslan, 2007, Redox-dependent impairment of vascular function in sickle cell disease., Free Radic Biol Med, 43, 1469, 10.1016/j.freeradbiomed.2007.08.014 · DOI
- Turhan, 2004, Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes., Blood, 103, 2397, 10.1182/blood-2003-07-2209 · DOI · Paper page
- Hidalgo, 2009, Heterotypic interactions enabled by polarized neutrophil microdomains mediate thromboinflammatory injury., Nat Med, 15, 384, 10.1038/nm.1939 · DOI · Paper page
- Chaar, 2010, Aggregation of mononuclear and red blood cells through α4β1-Lu/BCAM interaction in sickle cell disease., Haematologica, 95, 1841, 10.3324/haematol.2010.026294 · DOI
- Head, 2010, Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis., Am J Hematol, 85, 800, 10.1002/ajh.21832 · DOI
- Montero-Huerta, 2006, Inhaled nitric oxide for treatment of sickle cell stroke., Anesthesiology, 105, 619, 10.1097/00000542-200609000-00028 · DOI
- Kaul, 2008, Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress., Am J Physiol Heart Circ Physiol, 295, H39, 10.1152/ajpheart.00162.2008 · DOI · Paper page
- de Franceschi, 2003, Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation., Blood, 102, 1087, 10.1182/blood-2002-07-2135 · DOI · Paper page
- Martinez-Ruiz, 2001, Inhaled nitric oxide improves survival rates during hypoxia in a sickle cell (SAD) mouse model., Anesthesiology, 94, 1113, 10.1097/00000542-200106000-00028 · DOI
- Rosse, 2000, New views of sickle cell disease pathophysiology and treatment., Hematology Am Soc Hematol Educ Program, 2000, 2, 10.1182/asheducation.V2000.1.2.20000002 · DOI
- McGann, 2011, Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?, Curr Opin Hematol, 18, 158, 10.1097/MOH.0b013e32834521dd · DOI · Paper page
- King, 2004, Nitric oxide production from hydroxyurea., Free Radical Biol Med, 37, 737, 10.1016/j.freeradbiomed.2004.02.073 · DOI
- Cokic, 2003, Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase., J Clin Invest, 111, 231, 10.1172/JCI200316672 · DOI · Paper page
- Bender, 2006, Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use., Pharmacol Rev, 58, 488, 10.1124/pr.58.3.5 · DOI · Paper page
- Ikuta, 2001, Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway., Proc Nat Acad Sci U S A, 98, 1847, 10.1073/pnas.98.4.1847 · DOI
- Canalli, 2008, Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation., Haematologica, 93, 605, 10.3324/haematol.12119 · DOI · Paper page
- Almeida, 2008, High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils., Br J Haematol, 142, 836, 10.1111/j.1365-2141.2008.07264.x · DOI
- Miguel, 2011, Inhibition of phosphodiesterase 9A (PDE9A) reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals., Inflamm Res, 60, 633, 10.1007/s00011-011-0315-8 · DOI
- Jang, 2011, CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactions., J Clin Invest, 121, 1397, 10.1172/JCI45336 · DOI · Paper page
- Belcher, 2005, Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice., Am J Physiol Heart Circ Physiol, 288, H2715, 10.1152/ajpheart.00986.2004 · DOI · Paper page
- Kaul, 2000, Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice., J Clin Invest, 106, 411, 10.1172/JCI9225 · DOI · Paper page
- Lanaro, 2009, Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy., J Leukoc Biol, 85, 235, 10.1189/jlb.0708445 · DOI · Paper page
- Lebensburger, 2010, Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model., Haematologica, 95, 1599, 10.3324/haematol.2010.023325 · DOI
- Cokic, 2006, Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells., Blood, 108, 184, 10.1182/blood-2005-11-4454 · DOI
- Kato, 2009, Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions., Am J Hematol, 84, 618, 10.1002/ajh.21475 · DOI · Paper page
- Cokic, 2008, Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells., Blood, 111, 1117, 10.1182/blood-2007-05-088732 · DOI · Paper page
- Xu, 2011, Hydroxyurea enhances SMN2 gene expression through nitric oxide release., Neurogenetics, 12, 19, 10.1007/s10048-010-0268-z · DOI
- Rodriguez, 1998, A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea., Blood, 91, 1533, 10.1182/blood.V91.5.1533 · DOI
- Reyes-Irisarri, 2007, Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains., Eur J Neurosci, 25, 3332, 10.1111/j.1460-9568.2007.05589.x · DOI
- Wunder, 2005, Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line., Mol Pharmacol, 68, 1775, 10.1124/mol.105.017608 · DOI
- Lebensburger, 2012, Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin., Blood, 119, 1915, 10.1182/blood-2011-08-374447 · DOI
- Zarbock, 2008, PSGL-1 engagement by E-selectin signals through Src kinase Fgr and ITAM adapters DAP12 and FcR gamma to induce slow leukocyte rolling., J Exp Med, 205, 2339, 10.1084/jem.20072660 · DOI · Paper page
- Luo, 2007, Structural basis of integrin regulation and signaling., Annu Rev Immunol, 25, 619, 10.1146/annurev.immunol.25.022106.141618 · DOI · Paper page
- Tang, 2006, Down-regulation of integrin alpha M beta 2 ligand-binding function by the urokinase-type plasminogen activator receptor., Biochem Biophys Res Commun, 348, 1184, 10.1016/j.bbrc.2006.07.179 · DOI
- Machado, 2011, Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity., Blood, 118, 855, 10.1182/blood-2010-09-306167 · DOI · Paper page
- Hutson, 2011, The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents., Neuropharmacology, 61, 665, 10.1016/j.neuropharm.2011.05.009 · DOI
- Kroker, 2012, Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP., Neuropharmacology, 62, 1964, 10.1016/j.neuropharm.2011.12.021 · DOI
- Gladwin, 2002, Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease., Br J Haematol, 116, 436, 10.1046/j.1365-2141.2002.03274.x · DOI · Paper page
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Pathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies
Manwani, D., & Frenette, P. S. (2013) · Blood · doi:10.1182/blood-2013-05-498311 · Cited by 428
“Short-term administration of either hydroxyurea or phosphodiesterase inhibitor 9 (PDE9) ameliorated VOC in a SCDmurinemodel via cGMP-elevating effects, suggesting that hydroxyurea may have immediate benefit in the setting of VOC.(32) PDE9 is highly expressed in hematopoietic cells and is thus a promising therapeutic t…”
BackgroundSelf-citationZhang, D., Xu, C., Manwani, D., & Frenette, P. S. (2016) · Blood · doi:10.1182/blood-2015-09-618538 · Cited by 413
“Rivipansel (GMI-1070), a synthetic pan-selectin inhibitor, has been shown to inhibit predominantly E-selectin–mediated leukocyte adhesion and dramatically reduce RBC-leukocyte interactions, leading to improved blood flow and prolonged survival in SCD mice during VOC.79 In a phase 1 clinical trial, GMI-1070 has been we…”
InfluentialSelf-citationTherapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
Baillie, G. S., Tejeda, G. S., & Kelly, M. P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0033-4 · Cited by 339
Metadata
- Authors
- Almeida, C. B., Scheiermann, C., Jang, J.-E., Prophete, C., Costa, F. F., Conran, N., & Frenette, P. S.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-10-04
- Volume
- 120
- Issue
- 14
- Pages
- 2879-2888
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2027955104
- Cited by
- 116
- References
- 7
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. https://app.cochat.ai/papers/10.1182/blood-2012-02-409524
- The paper
- Almeida, C. B., Scheiermann, C., Jang, J.-E., Prophete, C., Costa, F. F., Conran, N., & Frenette, P. S. (2012). Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood. https://doi.org/10.1182/blood-2012-02-409524
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.